HUP0400530A2 - A1 adenozin receptor antagonista hatású kondenzált purinszármazékok - Google Patents

A1 adenozin receptor antagonista hatású kondenzált purinszármazékok

Info

Publication number
HUP0400530A2
HUP0400530A2 HU0400530A HUP0400530A HUP0400530A2 HU P0400530 A2 HUP0400530 A2 HU P0400530A2 HU 0400530 A HU0400530 A HU 0400530A HU P0400530 A HUP0400530 A HU P0400530A HU P0400530 A2 HUP0400530 A2 HU P0400530A2
Authority
HU
Hungary
Prior art keywords
alkyl
group
substituted
hydrogen atom
optionally substituted
Prior art date
Application number
HU0400530A
Other languages
English (en)
Inventor
Ko-Chung Lin
Chi Vu
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of HUP0400530A2 publication Critical patent/HUP0400530A2/hu
Publication of HUP0400530A3 publication Critical patent/HUP0400530A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

A találmány (I) és (II) általános képletű vegyületekre vonatkozik - aképletben R1 és R2 jelentése egymástól függetlenül a) hidrogénatom, b) adott esetben szubsztituált alkil-, alkenil-vagy alkinilcsoport, vagy c) aril- vagy szubsztituált arilcsoport; R3jelentése egy adott esetben szubsztituált biciklusos, triciklusos vagypentaciklusos csoport: R4 jelentése hidrogénatom, adott esetbenszubsztituált 1-4 szénatomos alkil-, 1-4 szénatomos alkil-CO2H vagyfenilcsoport, R5 jelentése: -(CR1R2)nCOOH, -C(CF3)20H, -CONHNHSO2CF3,-CONHOR4, -CONHSO2R4, -CONHSO2NHR4, -C(OH)R4PO3H2, -NHCOCF3, -NHCONHSO2R4, -NHPO3H2, -NHSO2R4, -NHSO2NHCOR4, -OPO3H2, -OSO3H, -PO(OH)R4, -PO3H2, -SO3H, -SO2NHR4, -SO3NHCOR4, -SO3NHCONHCO2R4 vagy nértéke 0, 1, 2 vagy 3, A jelentése valamely következő csoport: -CH=CH,-(CH)m-(CH)m, CH=CH-CH2 vagy -CH2-CH=CH; m értéke 1 vagy 2; Xjelentése O vagy S, Z jelentése egyeskötés, -O-, -(CH2)n-, -O(CH2)1,2-, -CH2OCH2-, -(CH2)1-2O-, és R6 jelentése hidrogénatom-,alkil-, acil-, alkilszulfonil-, aralkil-, szubsztituált aralkil-,szubsztituált alkil- vagy heterociklusos-csoport; és R7 jelentése: a)hidrogénatom; b) adott esetben szubsztituált alkil-, nem kevesebb,mint 3 szénatomot tartalmazó alkenil- vagy nem kevesebb, mint 3szénatomot tartalmazó alkinilcsoport; c) aril- vagy szubsztituáltarilcsoport; d) alkilaril- vagy arilcsoporttal szubsztituáltalkilcsoport. A fenti (I) általános képletű vegyületek A1 adenozinreceptor antagonista hatásúak. A találmány vonatkozik továbbá a fentivegyületeket tartalmazó gyógyszerkészítményekre. Ó
HU0400530A 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists HUP0400530A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0400530A2 true HUP0400530A2 (hu) 2004-06-28
HUP0400530A3 HUP0400530A3 (en) 2007-05-29

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400530A HUP0400530A3 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Country Status (33)

Country Link
US (2) US6605601B2 (hu)
EP (1) EP1347981B1 (hu)
JP (2) JP2004514723A (hu)
KR (1) KR20040011439A (hu)
CN (1) CN100497340C (hu)
AR (1) AR035400A1 (hu)
AT (1) ATE394402T1 (hu)
AU (2) AU2002219977B2 (hu)
BG (1) BG107849A (hu)
BR (1) BR0115833A (hu)
CA (1) CA2430508C (hu)
CZ (1) CZ20031513A3 (hu)
DE (1) DE60133931D1 (hu)
EA (1) EA009814B1 (hu)
EE (1) EE200300260A (hu)
ES (1) ES2305139T3 (hu)
GE (1) GEP20094697B (hu)
HK (1) HK1059927A1 (hu)
HU (1) HUP0400530A3 (hu)
IL (1) IL156046A0 (hu)
IS (1) IS6821A (hu)
MX (1) MXPA03004857A (hu)
MY (1) MY127120A (hu)
NO (1) NO20032483L (hu)
NZ (1) NZ526511A (hu)
PL (1) PL362642A1 (hu)
SK (1) SK6552003A3 (hu)
TR (1) TR200300766T2 (hu)
TW (1) TWI293301B (hu)
UA (1) UA75625C2 (hu)
WO (1) WO2002044182A1 (hu)
YU (1) YU42903A (hu)
ZA (2) ZA200304067B (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2238335T3 (es) * 1999-12-24 2005-09-01 Kyowa Hakko Kogyo Co., Ltd. Derivados de purina condensados.
GEP20094697B (en) * 2000-12-01 2009-06-10 Biogen Idec Inc Condensed purine derivatives as a1 adenosine receptor antagonists
US7202252B2 (en) * 2003-02-19 2007-04-10 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060252780A1 (en) * 2003-04-25 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. Fused pyrimidine derivatives
TW200500070A (en) 2003-04-25 2005-01-01 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
MX2007010984A (es) * 2005-03-11 2008-03-18 Aderis Pharmaceuticals Inc 9-alquiladeninas sustituidas y uso de las mismas.
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
DK2018380T3 (da) 2006-05-19 2012-01-23 Abbott Lab CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
ATE486874T1 (de) 2006-06-23 2010-11-15 Incyte Corp Purinonderivate als hm74a-agonisten
BRPI0713619A2 (pt) 2006-06-23 2013-01-15 Incyte Corp composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto.
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
KR20200106176A (ko) 2018-01-04 2020-09-11 임페티스 바이오사이언시즈 엘티디. 삼환식 화합물, 삼환식 화합물을 포함하는 조성물 및 이의 의약적 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
ES2152207T3 (es) * 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.
EP0884314B1 (en) 1991-09-23 2004-01-21 Florida State University Metal alkoxides
EP0884318A4 (en) * 1996-10-07 2002-10-23 Kyowa Hakko Kogyo Kk CONDENSED PURINE DERIVATIVES
WO1998057651A1 (en) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
CA2336412C (en) * 1998-07-02 2007-11-27 Junichi Shimada Medicament for treatment of diabetes
ES2238335T3 (es) * 1999-12-24 2005-09-01 Kyowa Hakko Kogyo Co., Ltd. Derivados de purina condensados.
GEP20094697B (en) * 2000-12-01 2009-06-10 Biogen Idec Inc Condensed purine derivatives as a1 adenosine receptor antagonists

Also Published As

Publication number Publication date
US6605601B2 (en) 2003-08-12
IS6821A (is) 2003-05-20
YU42903A (sh) 2006-05-25
EA200300629A1 (ru) 2003-12-25
GEP20094697B (en) 2009-06-10
JP2004514723A (ja) 2004-05-20
ATE394402T1 (de) 2008-05-15
NO20032483L (no) 2003-07-30
HUP0400530A3 (en) 2007-05-29
CZ20031513A3 (cs) 2003-09-17
MXPA03004857A (es) 2003-08-19
EE200300260A (et) 2003-08-15
HK1059927A1 (en) 2004-07-23
KR20040011439A (ko) 2004-02-05
UA75625C2 (en) 2006-05-15
ZA200408755B (en) 2005-07-27
ZA200304067B (en) 2005-05-30
BG107849A (bg) 2004-01-30
SK6552003A3 (en) 2003-12-02
TWI293301B (en) 2008-02-11
US20020111333A1 (en) 2002-08-15
EP1347981A1 (en) 2003-10-01
AU2002219977B2 (en) 2008-01-24
DE60133931D1 (de) 2008-06-19
JP2010053148A (ja) 2010-03-11
EA009814B1 (ru) 2008-04-28
WO2002044182A1 (en) 2002-06-06
NO20032483D0 (no) 2003-06-02
ES2305139T3 (es) 2008-11-01
EP1347981B1 (en) 2008-05-07
PL362642A1 (en) 2004-11-02
IL156046A0 (en) 2003-12-23
NZ526511A (en) 2005-04-29
CN100497340C (zh) 2009-06-10
US7022686B2 (en) 2006-04-04
BR0115833A (pt) 2003-10-28
US20030220358A1 (en) 2003-11-27
AR035400A1 (es) 2004-05-26
CN1481387A (zh) 2004-03-10
CA2430508C (en) 2010-05-18
AU1997702A (en) 2002-06-11
CA2430508A1 (en) 2002-06-06
TR200300766T2 (tr) 2004-09-21
MY127120A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
HUP0400530A2 (hu) A1 adenozin receptor antagonista hatású kondenzált purinszármazékok
HUP0302962A2 (hu) Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása
HUP9802300A2 (hu) N-heteroaril-piridin-szulfonamid származékok, ezeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP9701269A2 (hu) Abszorbens készítmény savas komponenseket tartalmazó gázok tisztítására
HUP0100889A2 (hu) Tumorellenes hatású 6,9-diszubsztituált, 2-{transz-(4-amino-ciklohexil)-amino}-purinok és azokat tartalmazó gyógyszerkészítmények
ATE110075T1 (de) 1,2-benzisoxazolderivate, verfahren zu deren herstellung, und sie enthaltende pharmazeutische zusammensetzungen.
DE3853477D1 (de) Makrozyklische verbindungen.
HUP0001494A2 (hu) 3-Fenoxi-, 3-dibenzo[a,d]cikloheptenil-oxi-, 3-dibenz[b,f]-[1,4]oxazepinil-oxi-1-amino-2-propanol-származékok és az ezeket tartalmazó gyógyszerkészítmények
HUP9802937A2 (hu) Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP9700992A2 (hu) 3-(Piperid-4-il)-1,2-benzizoxazol- és 3-(piperazin-4-il)-1,2-benzizoxazol-származékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
ATE94061T1 (de) Arylsubstituierte aminderivate verwendbar in der krebstherapie.
ATE250623T1 (de) 4'-c-ethynyl-purin-nukleoside
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
HUP0003826A2 (hu) Új triazolo [4,5-d] pirimidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES8301881A1 (es) Un procedimiento para la preparacion de derivados de ariletanolamina que tienen actividad antiobesidad yno hploglicemi- ca.
DE60010596D1 (de) Pyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
HUP0002311A2 (hu) Ergolinszármazékok és szomatosztatin receptorként való alkalmazásuk
ATE73780T1 (de) Glutaminsaeure-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische formulierungen.
SE9904129D0 (sv) Novel compounds
FI922983A (fi) Pyrimidin-4-karboxamidderivat, framstaellning av dessa och terapeutisk anvaendning av dessa
HUP0203471A2 (hu) Trombózisellenes hatású vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CO4990965A1 (es) Derivados de 1,3,8-triazaspiro(4,5)decan-4-ona to que los contiene y un proceso para la preparacion de es- tos derivados
HUP0004085A2 (hu) A 9a-azaleidek csoportjához tartozó, új 3,6-hemiketálszármazékok
HUP0303184A2 (hu) Szubsztituált C-ciklohexil-metil-amin-származékok és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees